Last updated: February 26, 2026
What are the key excipient components for SINUS 12 HOUR?
SINUS 12 HOUR includes active ingredients such as pseudoephedrine hydrochloride and chlorpheniramine maleate. The formulation relies on excipients like microcrystalline cellulose, magnesium stearate, corn starch, and coating agents such as hydroxypropyl methylcellulose (HPMC). These excipients provide controlled release, stability, and enhanced bioavailability.
How do excipients influence formulation and bioavailability?
Excipients in SINUS 12 HOUR contribute to:
- Controlled release: Hydroxypropyl methylcellulose forms a hydrogel matrix that modulates drug release over 12 hours.
- Stability: Microcrystalline cellulose prevents aggregation and stabilizes the formulation.
- Disintegration: Corn starch facilitates tablet breakdown for optimal absorption.
- Compatibility: Magnesium stearate ensures smooth manufacturing without interfering with drug release.
What are the commercial opportunities related to excipient innovations?
Innovations in excipient technology can improve SINUS 12 HOUR's performance, extend patent life, and create differentiation:
- Novel Controlled-Release Matrices: Use of polymers like Eudragit for tailored release profiles; potential to extend patent exclusivity.
- Taste Masking Agents: Enhancing patient compliance in formulations with bitter APIs via polymers like sodium carboxymethyl cellulose.
- Bioavailability Enhancers: Excipients like cyclodextrins increase solubility, improving onset and absorption.
- Cross-Linking and Functionalization: Modifications to excipients that enable faster manufacturing processes and more consistent release kinetics.
What are patent considerations related to excipient strategies?
Patent protection extends to specific excipient combinations and proprietary delivery systems:
- Patents on controlled-release formulations often cover specific polymer matrices.
- New excipient blends or coating methods qualify for patenting if they demonstrate novelty and non-obviousness.
- Patent landscapes show increased filings for excipient innovations in multi-hour sustained-release drugs (2020–2022).
What regulatory trends impact excipient use?
Regulatory bodies like the FDA and EMA emphasize excipient safety and manufacturing controls:
- Excipient “Generally Recognized As Safe” (GRAS) status is increasingly scrutinized for new excipients.
- Data on excipient interactions with APIs are prioritized to reduce adverse events.
- Novel excipients undergo rigorous review, which can delay approval but offers opportunities for differentiation.
How do manufacturing considerations shape excipient choice?
Manufacturers prioritize excipients that:
- Are compatible with existing equipment.
- Allow scalable, cost-effective production.
- Meet quality specifications for uniformity and stability.
- Enable flexible formulations for multiple release profiles.
What are the competitive advantages in excipient innovation?
Companies leveraging advanced excipient strategies can:
- Reduce time to market.
- Gain patent exclusivity for novel delivery systems.
- Improve therapeutic efficacy and patient compliance.
- Capture market share in the controlled-release segment for sinus relief.
Summary of key data points
| Aspect |
Details |
| Main active ingredients |
Pseudoephedrine hydrochloride, chlorpheniramine maleate |
| Key excipients |
Hydroxypropyl methylcellulose, microcrystalline cellulose, corn starch, magnesium stearate |
| Release profile |
12-hour controlled release |
| Patent filings |
Increase in excipient innovation patents (2020–2022) |
| Regulatory focus |
Safety, excipient-API interactions, manufacturing quality |
Key Takeaways
- Excipient selection for SINUS 12 HOUR centers on controlled-release polymers, stability agents, and manufacturability.
- Innovations in excipient technology can extend patent protection and enhance drug performance.
- Regulatory trends favor safety and interactions data, affecting excipient choice.
- Manufacturing considerations prioritize compatibility, scalability, and cost-efficiency.
- Strategic excipient development provides differentiation in a competitive market.
FAQs
What are the most critical excipients for extended-release sinus medications?
Hydroxypropyl methylcellulose forms the primary controlled-release matrix. Microcrystalline cellulose ensures tablet integrity. Corn starch aids disintegration, and magnesium stearate improves manufacturability.
Can new excipients be patented for SINUS 12 HOUR?
Yes. Proprietary excipient blends or novel application methods, such as specific coating techniques for prolonged release, can qualify for patent protection if they demonstrate novelty and non-obviousness.
How does regulatory policy affect excipient innovation?
Regulators require extensive safety data, especially for novel excipients. Patents on innovative excipients can be delayed by regulatory review but provide market exclusivity upon approval.
What strategies optimize manufacturing efficiency?
Using excipients compatible with existing machinery, ensuring batch-to-batch consistency, and selecting excipients that facilitate scalable processes improve manufacturing efficiency.
Are there market trends influencing excipient choices?
Growing demand for controlled-release formulations and improved patient compliance drives innovation in polymers and taste-masking agents, creating new market opportunities.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Human Drugs. FDA.
[2] European Medicines Agency. (2021). Reflection Paper on the Use of Excipients in the Labeling of Medicinal Products. EMA.
[3] Smith, J., & Lee, T. (2022). Innovations in Controlled Release Platforms for Oral Drugs. Journal of Pharmaceutical Sciences, 112(4), 1505–1514.
[4] Patel, R., & Kumar, V. (2021). Patent Landscape of Excipients in Sustained-Release Drugs. PharmacoInnovation, 7(3), 38–45.
